z-logo
Premium
Low‐fat dairy reduces inflammatory genes and liver enzymes in adults with metabolic syndrome (40.5)
Author(s) -
AGuilar David,
Dugan Christine,
Park YoungKi,
Lee JiYoung,
Fernandez Maria Luz
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.40.5
Subject(s) - peripheral blood mononuclear cell , medicine , alanine aminotransferase , endocrinology , inflammation , metabolic syndrome , tumor necrosis factor alpha , liver enzyme , monocyte , gene expression , biology , gene , obesity , biochemistry , in vitro
We evaluated the effect of low‐fat dairy (LFD) intake on plasma inflammatory markers, gene expression of these markers in peripheral blood mononuclear cells (PBMC) and liver enzymes in individuals with metabolic syndrome (MetS). Subjects (13 male, 22 female) with low dairy intake (<1.5 ser/dairy/day) were randomly assigned to receive LFD (296 mL low‐fat milk, 170 g yogurt, 510 g cheese stick, 3 servings of dairy/day) or isocaloric control foods (CON) (42 g granola bar, 177 mL juice) daily for 6‐wk. After a 4‐wk wash‐out, subjects were allocated to the alternate treatment. Participants had lower concentrations of both hepatic alanine aminotransferase (ALT) (p < 0.05) and aspartate aminotransferase (AST) (p< 0.005) as well as lower concentrations of plasma monocyte chemoattractant protein (MPC‐1) (p<0.05) after the LFD period. Gene expression was evaluated in a subset of subjects (n = 17). IL‐1b and IL‐6 were reduced by 46 and 63%, respectively compared to the control period. Protein and gene expression of tumor necrosis factor (TNF)‐alpha was not altered by diet. These results indicate that consumption of three dairy servings per day improve both liver inflammatory markers and systemic inflammation in subjects with MetS. Grant Funding Source : Dairy Council

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here